Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
May 6, 2021 4:05 PM EDT- Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS as the first approved oral therapy for lupus nephritis (LN) -
- Over 250 patient start forms received by the end of the first quarter -
- Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 -
- Conference call to be hosted today at 5:00 p.m. ET -
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the... More
